Tags

Type your tag names separated by a space and hit enter

Role of angiotensin II in the evolution of diastolic heart failure.

Abstract

More than half of all persons with heart failure (HF) have diastolic HF. The prevalence of diastolic HF increases from 46% in persons younger than 45 years to 59% in those 85 years and older. The annual mortality rate associated with diastolic HF is >10%. Diagnosis is based on signs and symptoms of HF, elevated plasma B-type natriuretic peptide, preserved left ventricular systolic function, and evidence of diastolic dysfunction by Doppler examination on two-dimensional echocardiography. Approximately 80% of patients with diastolic HF have increased left ventricular mass and a history of hypertension. Neurohormonal activation is a key aspect of this condition. Studies suggest that activation of the renin-angiotensin-aldosterone system, specifically direct cardiac effects of angiotensin II and aldosterone, contributes to the pathogenesis and progression of diastolic dysfunction. Hence, there is a rationale for use of agents that antagonize the renin-angiotensin-aldosterone system, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists, in patients with heart failure.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Division of Cardiology and Nutrition, William Beaumont Hospital, Royal Oak, MI 48073, USA.

    ,

    Source

    MeSH

    Angiotensin II
    Angiotensin Receptor Antagonists
    Angiotensin-Converting Enzyme Inhibitors
    Blood Pressure
    Heart Failure
    Humans
    Hypertension
    Hypertrophy, Left Ventricular
    Mineralocorticoid Receptor Antagonists
    Prognosis
    Renal Insufficiency
    Renin-Angiotensin System
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    16330897

    Citation

    Chinnaiyan, Kavitha M., et al. "Role of Angiotensin II in the Evolution of Diastolic Heart Failure." Journal of Clinical Hypertension (Greenwich, Conn.), vol. 7, no. 12, 2005, pp. 740-7.
    Chinnaiyan KM, Alexander D, McCullough PA. Role of angiotensin II in the evolution of diastolic heart failure. J Clin Hypertens (Greenwich). 2005;7(12):740-7.
    Chinnaiyan, K. M., Alexander, D., & McCullough, P. A. (2005). Role of angiotensin II in the evolution of diastolic heart failure. Journal of Clinical Hypertension (Greenwich, Conn.), 7(12), pp. 740-7.
    Chinnaiyan KM, Alexander D, McCullough PA. Role of Angiotensin II in the Evolution of Diastolic Heart Failure. J Clin Hypertens (Greenwich). 2005;7(12):740-7. PubMed PMID: 16330897.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Role of angiotensin II in the evolution of diastolic heart failure. AU - Chinnaiyan,Kavitha M, AU - Alexander,Daniel, AU - McCullough,Peter A, PY - 2005/12/7/pubmed PY - 2007/4/11/medline PY - 2005/12/7/entrez SP - 740 EP - 7 JF - Journal of clinical hypertension (Greenwich, Conn.) JO - J Clin Hypertens (Greenwich) VL - 7 IS - 12 N2 - More than half of all persons with heart failure (HF) have diastolic HF. The prevalence of diastolic HF increases from 46% in persons younger than 45 years to 59% in those 85 years and older. The annual mortality rate associated with diastolic HF is >10%. Diagnosis is based on signs and symptoms of HF, elevated plasma B-type natriuretic peptide, preserved left ventricular systolic function, and evidence of diastolic dysfunction by Doppler examination on two-dimensional echocardiography. Approximately 80% of patients with diastolic HF have increased left ventricular mass and a history of hypertension. Neurohormonal activation is a key aspect of this condition. Studies suggest that activation of the renin-angiotensin-aldosterone system, specifically direct cardiac effects of angiotensin II and aldosterone, contributes to the pathogenesis and progression of diastolic dysfunction. Hence, there is a rationale for use of agents that antagonize the renin-angiotensin-aldosterone system, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists, in patients with heart failure. SN - 1524-6175 UR - https://www.unboundmedicine.com/medline/citation/16330897/Role_of_angiotensin_II_in_the_evolution_of_diastolic_heart_failure_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1524-6175&date=2005&volume=7&issue=12&spage=740 DB - PRIME DP - Unbound Medicine ER -